SGCA
TCRT icon

Steel Grove Capital Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Steel Grove Capital Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-67
Closed -$5.1K – 205
2023
Q2 		$5.1K Hold
67
– – ﹤0.01% 196
2023
Q1 		$6.3K Sell
67
-18,133
-100% -$1.73M ﹤0.01% 189
2022
Q4 		$1.77M Buy
18,200
+11,000
+153% +$1.59M 0.25% 65
2022
Q3 		$1.86M Buy
7,200
+1,537
+27% +$446K 0.33% 40
2022
Q2 		$1.05M Buy
+5,663
New +$541K 0.19% 70

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Steel Grove Capital Advisors's TCRT Position: Q3 2023 in Review

Steel Grove Capital Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2023, closing a stake of 67 shares — an estimated $5.1K sold.

Steel Grove Capital Advisors first reported a position in TCRT in Q2 2022 and held it in 5 quarters. The position peaked at $1.86M in Q3 2022. 89 funds tracked by Wall St. Rank hold TCRT as of Q3 2023.

  • Steel Grove Capital Advisors reported no remaining Alaunos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Steel Grove Capital Advisors sold 67 Alaunos Therapeutics shares in Q3 2023, an estimated $5.1K.
  • Steel Grove Capital Advisors first reported a position in Alaunos Therapeutics in Q2 2022 and held it in 5 quarters.
  • Steel Grove Capital Advisors's Alaunos Therapeutics position peaked at $1.86M in Q3 2022.
  • 89 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2023.

Based on Steel Grove Capital Advisors's 13F filing for Q3 2023, filed 10 Oct 2023.